Literature DB >> 2151334

Left ventricular hypertrophy, arterial hypertension and sudden death.

F H Messerli1.   

Abstract

Left ventricular hypertrophy has been identified as a powerful risk factor for sudden death and for general cardiovascular morbidity and mortality. Left ventricular hypertrophy has been documented as giving rise to ventricular ectopy, even in the absence of myocardial ischemia. Mechanisms of ectopic impulse generation in left ventricular hypertrophy are multifactorial and involve enlarged myocytes, focal areas of fibrosis, and subendocardial ischemia, as well as medial hypertrophy of the coronary arteries impeding homogeneous impulse propagation throughout the myocardium. Left ventricular hypertrophy can be reduced by specific antihypertensive therapy although not all antihypertensive agents are equally effective. A reduction of left ventricular hypertrophy with calcium antagonists, and possibly also with beta-blockers, has been shown to diminish ventricular arrhythmias. Whether or not such a reduction of left ventricular hypertrophy and suppression of ventricular ectopy will improve their unfavorable prognosis remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2151334

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  4 in total

Review 1.  Sudden adult death.

Authors:  Neil E I Langlois
Journal:  Forensic Sci Med Pathol       Date:  2009-07-18       Impact factor: 2.007

Review 2.  Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy.

Authors:  C Morisco; L Argenziano; N Tozzi; A F Mele; B Ricciardelli; G Condorelli; B Trimarco
Journal:  Drugs       Date:  1993       Impact factor: 9.546

3.  Fragmented QRS: A marker of hypertensive heart disease?

Authors:  Arya Mani
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-07-18       Impact factor: 3.738

4.  Case 5: a 73 year-old man with heart failure, preserved systolic function and associated renal failure.

Authors:  Tiago Rodrigues Politi; Paulo Sampaio Gutierrez
Journal:  Arq Bras Cardiol       Date:  2013-11       Impact factor: 2.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.